Which medication has a specific role for a rare genetic obesity option in adolescents aged 6 and older?

• A. Setmelanotide
• B. Phentermine
• C. Semaglutide
• D. Topiramate

Answer: (A)

Targeted therapy for rare genetic obesity in kids focuses on the specific pathway that drives excessive hunger. Setmelanotide is a selective MC4 receptor agonist approved for obesity caused by defects in the MC4R signaling pathway—such as POMC deficiency, LEPR deficiency, or PCSK1 deficiency—and it is approved for children age 6 and older. By activating MC4R, it helps restore the diminished signaling that reduces appetite, leading to weight loss in these particular genetic conditions. The other medications do not address this genetic mechanism: phentermine is a general appetite suppressant not specifically approved for young children with genetic obesity; semaglutide acts as a GLP-1 receptor agonist for obesity management without targeting a genetic defect; topiramate is not a genetic-obesity–specific therapy. So, setmelanotide is the appropriate choice for a rare genetic obesity option in adolescents 6 and older.